TSHA-102 — Topline data
H1 2027
Topline data from REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 is expected in the first half of 2027Source filing
TSHA biotech catalysts & pipeline
TAYSHA GENE THERAPIES INC · Data as of 2026-09-08
Upcoming catalysts
TSHA-102 — Regulatory decision
1H 2027
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027Source filing